natgillin/translations-raw huggingface dataset:
EU/2/04/047/001 lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml) EU/2/04/047/002 lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml) 
EU/2/04/047/001 Liofilizat (10 stekleničk z 1 odmerkom) in vehikel (10 stekleničk po 1 ml) EU/2/04/047/002 Liofilizat (50 stekleničk z 1 odmerkom) in vehikel (50 stekleničk po 1 ml)
Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the product. 
Ne mešajte z nobenim drugim zdravilom razen s topilom, ki je priloženo za uporabo s tem cepivom.
Special precautions to be taken by the person administering the veterinary medicinal product to animals: In case of accidental self-injection, seek medical advice immediately and show the package insert or the label to the physician. 
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo: V primeru nenamernega samo-injiciranja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali nalepko na zunanji ovojnini.
Revaccination: - the first revaccination must be carried out for all components one year after the primary vaccination course, - subsequent revaccinations must be carried out: every year for the chlamydiosis and feline leukaemia components and at intervals of up to three years for the rhinotracheitis, calicivirosis and panleucopenia components. 
Ponovno cepljenje: - prvo ponovno cepljenje je potrebno opraviti za vse komponente eno leto po osnovnem cepljenju, - nadaljnja ponovna cepljenja je potrebno opraviti: vsako leto za komponenti klamidioza in leukemija mačk in v obdobjih do 3 leta za komponente rinotraheitisa, kaliciviroze in panleukopenije.
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND 
A. IZDELOVALCI BIOLOŠKIH ZDRAVILNIH UČINKOVIN IN IMETNIK
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals ) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). 
- pogosti (pojavijo se pri več kot 1 toda manj kot pri 10 živalih od 100 živali) - občasni (pojavijo se pri več kot 1 toda manj kot pri 10 živalih od 1.000 živali) - redki (pojavijo se pri več kot 1 toda manj kot pri 10 živalih od 10.000 živali)
The product was shown to reduce excretion of feline calicivirus at onset of immunity and for one year after vaccination. 
Cepivo dokazano zmanjša izločanje kalicivirusa mačk ob nastopu imunosti in do enega leta po cepljenju.
As a consequence, the vaccine induces an immune status against feline leukaemia virus. 
Posledica tega je, da cepivo vzpodbudi imunski odgovor proti virusu mačje levkemije.
The feline leukaemia vaccine strain is a recombinant canarypox virus expressing the env and gag genes of FeLV-A. 
Sev virusa v cepivu proti mačji levkemiji je rekombinantni poxvirus kanarčkov, ki izraža env in gag gene FeLV-A.
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALCI BIOLOŠKIH ZDRAVILNIH UČINKOVIN IN IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJE
No effect other than those already mentioned in section 4.6 “Adverse reactions” have been observed, except hyperthermia that may exceptionally last 5 days. 
4.10 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi), če je potrebno Drugi učinki, razen tistih, ki so navedeni v poglavju 4.6 »Neželeni učinki«, niso znani, razen povišane temperature , ki izjemoma lahko traja pet dni.
Purevax RCPCh FeLV lyophilisate and solvent for suspension for injection 
Purevax RCPCh FeLV liofilizat in vehikel za suspenzijo za injiciranje
The duration of immunity after the last re-vaccination is 3 years for the rhinotracheitis, calicivirosis and panleucopenia components, and 1 year for the Chlamydophila felis and feline leukaemia components. 
Trajanje imunosti je 3 leta po zadnjem ponovnem cepljenju za komponente kužnega rinotraheitisa, kaliciviroze in panleukopenije, ter 1 leto za komponenti Chlamydophila felis in leukemija mačk.
Disodium phosphate dihydrate Magnesium chloride hexahydrate Calcium chloride dihydrate 
Natrijev hidrogenfosfat dihidrat Magnezijev klorid heksahidrat Kalcijev klorid dihidrat
For the full list of excipients, see section 6.1. 
2 50% infektivni odmerek za embrionirana kokošja jajca Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
Inject by subcutaneous route one dose (1 ml) of vaccine after reconstitution of the lyophilisate with the solvent, according to the following vaccination scheme: 
Po rekonstituciji liofilizirane sestavine z vehiklom injicirajte odmerek (1-ml) cepiva v podkožje, po naslednjem razporedu:
Active immunisation of cats aged 8 weeks and older: - against feline viral rhinotracheitis to reduce clinical signs, - against calicivirus infection to reduce clinical signs, - against Chlamydophila felis infection to reduce clinical signs, - against feline panleucopenia to prevent mortality and clinical signs, - against leukaemia to prevent persistent viraemia and clinical signs of the related disease. 
Aktivna imunizacija 8 tednov starih mačk in starejših: - proti kužnemu rinotraheitisu mačk, za ublažitev kliničnih znamenj, - proti okužbam s kalicivirusi, za ublažitev kliničnih znamenj,
In very rare* cases, hyperthermia and lethargy sometimes associated with lameness has been observed one to three weeks following booster vaccination in adult cats. 
V zelo redkih primerih* sta se en teden do tri tedne po ponovnem cepljenju pri odraslih mačkah pojavili prehodna hipertermija in letargičnost, včasih tudi v povezavi s šepanjem.
It is recommended that a test for FeLV antigenaemia be carried out prior to vaccination. 
Pred cepljenjem je priporočljivo opraviti test na prisotnost antigenov FeLV v krvi.
Stimulates active immunity against feline rhinotracheitis herpesvirus, feline calicivirus, Chlamydophila felis, feline panleucopenia virus and feline leukaemia virus. 
Vzpodbuja aktivno imunost proti herpesvirusu kužnega rinotraheitisa, kalicivirusu, Chlamydophila felis, ter virusu panleukopenije in leukemije mačk.
2 egg infective dose 50% 
1 50% infektivni odmerek za celično kulturo 2 50% infektivni odmerek za embrionirana kokošja jajca
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) ....................................... ≥ 104.9 CCID501 Inactivated feline calicivirus (FCV 431 and G1 strains) antigens ................................... ≥ 2.0 ELISA U. Attenuated Chlamydophila felis (905 strain) ...................................................................... ≥ 103.0 EID502 Attenuated feline panleucopenia virus (PLI IV) ............................................................. ≥ 103.5 CCID501 
Inaktivirani antigeni kalici virusa mačk (seva FCV 431 in G1) ....................... ≥ 2,0 enot v testu ELISA Atenuirana Chlamydophila felis (sev 905) ......................................................................... ≥ 103,0 EID502 Atenuiran virus panleukopenije mačk (PLI IV) .............................................................. ≥ 103,5 CCID501
In normal conditions of use, transient apathy and anorexia may occasionally occur, as well as hyperthermia (lasting usually for 1or 2 days). 
Pri normalnih pogojih uporabe se lahko občasno pojavijo prehodna apatija in neješčnost.
Manufacturer responsible for the batch release: MERIAL 
Izdelovalec, odgovoren za sproščanje serij:
Where high levels of maternal antibodies against rhinotracheitis, calicivirosis, panleucopenia or Chlamydophila components are expected to be present (e.g. in kittens of 9-12 weeks of age born from queens, which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age. 
ki so bile cepljene pred brejostjo in/ali je znano ali verjetno, da so bile predhodno izpostavljene patogenu (om)), je potrebno osnovno cepljenje odložiti do starosti 12 tednov.
Laboratoire Porte des Alpes Rue de l'Aviation 
Laboratoire Porte des Alpes Rue de l'Aviation 69800 Saint Priest FRANCIJA
Special precautions for use in animals: 
Posebni previdnostni ukrepi za uporabo pri živalih: Cepite le zdrave živali.
Vaccine against feline viral rhinotracheitis, feline calicivirosis, chlamydiosis, feline panleucopenia and feline leukaemia. 
Cepivo proti virusnemu rinotraheitisu, kalicivirusu, klamidiozi, panleukopeniji in leukemiji mačk.
FeLV recombinant canarypox virus (vCP97) .................................................................. ≥ 107.2 CCID501 1 cell culture infective dose 50%. 
(vCP97) ............................................................................................................................. ≥ 107,2 CCID501
Per dose of 1 ml: FHV (F2 strain) ................................................................................................................. ≥ 104.9 CCID50 
V odmerku po 1 ml: FHV (sev F2) ..................................................................................................................... ≥ 104,9 CCID50
In normal conditions of use, transient apathy and anorexia may occasionally occur, as well as hyperthermia (lasting usually for 1 or 2 days). 
Lahko se pojavi tudi povišana telesna temperatura (običajno traja 1 do 2 dni).
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus, Chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. 
Imunost proti kužnemu rinotraheitisu, okužbam s kalicivirusi, okužbam s Chlamydophila felis in panleukopeniji mačk nastopi 1 teden po osnovnem cepljenju.
Where high levels of maternal antibodies against rhinotracheitis, calicivirosis, panleucopenia or Chlamydophila components are expected to be present (e.g. in kittens of 9-12 weeks of age born from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age. 
panleukopenije ali Chlamydophile (na primer pri mladičih starih od 9 do 12 tednov, rojenih mačkam,
Disodium hydrogen orthophosphate Monopotassium phosphate anhydrous Potassium chloride 
Natrijev hidrogenfosfat Kalijev dihidrogenfosfat, brezvodni Kalijev klorid
FeLV recombinant canarypox virus (vCP97)................................................................... ≥ 107.2 CCID50. 
Atenuirani herpes virus rinotraheitisa mačk (sev FHV F2) ............................................. ≥ 104,9 CCID501
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) ....................................... ≥ 104.9 CCID501 Inactivated feline calicivirus (FCV 431 and FCV G1 strains) antigens .......................... ≥ 2.0 ELISA U. Attenuated Chlamydophila felis (905 strain) ...................................................................... ≥ 103.0 EID502 Attenuated feline panleucopenia virus (PLI IV) ............................................................. ≥ 103.5 CCID501 
Inaktivirani antigeni kalici virusa mačk (sev FCV 431 in G1) ......................... ≥ 2,0 enot v testu ELISA
Gentamicin, at most .......................................................................................................................... 34 µg Solvent: 
Gentamicin, največ ........................................................................................................................... 34 µg Vehikel:
As the company had supplied additional information requested, the ‘exceptional circumstances' ended on 6 May 2013. 
Ker je podjetje predložilo zahtevane dodatne informacije, so „izjemne okoliščine“ prenehale veljati 6. maja 2013.
Further information on BTVPUR can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports. 
Nadaljnje informacije o zdravilu BTVPUR so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Other information about BTVPUR: 
Druge informacije o zdravilu BTVPUR:
BTVPUR received a marketing authorisation valid throughout the EU on 12 April 2016. 
Zdravilo BTVPUR je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 12. aprila 2016.
The second injection is given three to four weeks later. 
Drugi odmerek se živalim injicira od tri do štiri tedne pozneje.
BTVPUR is a vaccine. 
Zdravilo BTVPUR je cepivo.
The European Medicines Agency decided that BTVPUR's benefits are greater that its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je odločila, da so koristi zdravila BTVPUR večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
What is BTVPUR and what is it used for? 
Kaj je zdravilo BTVPUR in za kaj se uporablja?
Vaccination may be followed by a small local swelling at the injection site, which normally resolves within five weeks. 
Po cepljenju se lahko pojavi majhna oteklina na mestu injiciranja, ki običajno izzveni v petih tednih.
BTVPUR is developed using data from the vaccine BTVPUR AlSap 1-8 originally authorised under ‘exceptional circumstances' on 17 December 2010 because limited information was available at the time of approval. 
Zdravilo BTVPUR je bilo razvito z uporabo podatkov iz cepiva BTVPUR AlSap 1-8, ki je prvotno 17. decembra 2010 pridobilo dovoljenje za promet „v izjemnih okoliščinah“, saj so bile ob odobritvi na voljo le omejene informacije.
The withdrawal period for meat and milk from sheep and cattle treated with BTVPUR is ‘zero' days, which means that there is no mandatory waiting time. 
Karenca za meso in mleko ovac in goveda, zdravljenih z zdravilom BTVPUR, je „nič“ dni, kar pomeni, da ni obvezne čakalne dobe.
The vaccine is used to prevent viraemia (the presence of viruses in the blood) and reduce the signs of the disease. 
Uporablja se za preprečevanje viremije (prisotnosti virusa v krvi) in zmanjšanje znakov bolezni.
For more information about using BTVPUR see the package leaflet or contact your veterinarian or pharmacist. 
Za več informacij glede uporabe zdravila BTVPUR glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.
The vaccine also contains ‘adjuvants' (aluminium hydroxide and saponin) that enhance the response of the immune system. 
Cepivo vsebuje tudi „adjuvansa“ (aluminijev hidroksid in saponin) za povečanje imunskega odziva.
Why is BTVPUR authorised in the EU? 
Zakaj je zdravilo BTVPUR odobreno v EU?
There can also be a slight rise in body temperature, usually of no more than 1 °C, in the 24 hours following vaccination. 
V 24 urah po cepljenju se lahko pojavi tudi rahlo povišanje telesne temperature, običajno za največ za 1 °C.
Previously known as BTVPUR AlSap 1-8 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Predhodno znano kot BTVPUR AlSap 1-8 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom imunski sistem prepozna viruse kot tujke in proti njim razvije protitelesa.
An overview of BTVPUR and why it is authorised in the EU 
Pregled zdravila BTVPUR in zakaj je odobreno v EU
The vaccine is given to young animals as two injections under the skin. 
Cepivo se mladičem injicira pod kožo v dveh odmerkih.
What benefits of BTVPUR have been shown in studies? 
Kakšne koristi je zdravilo BTVPUR izkazalo v študijah?
In 2016 the CVMP considered that data submitted allowed BTVPUR AlSap 1-8 to convert to a BTVPUR vaccine based on three possible serotypes with one or two serotypes selected depending on the need. 
Leta 2016 je odbor CVMP menil, da je na podlagi predloženih podatkov mogoče zdravilo BTVPUR AlSap 1-8 spremeniti v cepivo BTVPUR na podlagi treh možnih serotipov z enim ali dvema serotipoma, izbranima glede na potrebe.
What are the risks associated with BTVPUR? 
Kakšna tveganja so povezana z zdravilom BTVPUR?
For a vaccine containing only bluetongue virus serotype 2 or 4 (or both together) in sheep, one injection is sufficient. 
Pri cepivu za ovce, ki vsebuje samo serotip 2 ali 4 virusa modrikastega jezika (oziroma oba skupaj), zadostuje le ena injekcija.
In 2018 a fourth possible serotype was added still with one or two serotypes selected depending on the need. 
Leta 2018 je bil dodan četrti možni serotip, še vedno pa velja, da se uporabi sam ali v kombinaciji z drugim izbranim serotipom glede na potrebe.
The company also presented results from a series of studies conducted with vaccines of similar composition but including different serotypes from the ones in BTVPUR to provide supportive information that could be used to calculate the effectiveness of the vaccine. 
Podjetje je predstavilo tudi rezultate niza študij, izvedenih s cepivi s podobno sestavo, ki pa so vključevali serotipe, drugačne od serotipov v zdravilu BTVPUR, da bi pridobili nadaljnje zaključke o učinkovitosti cepiva.
BTVPUR contains bluetongue viruses that have been inactivated so that they cannot cause the disease. 
Zdravilo BTVPUR vsebuje viruse modrikastega jezika, ki so inaktivirani in ne morejo povzročiti bolezni.
The variety (serotype) of the virus in the vaccine is selected depending on which serotypes are circulating and causing disease at the time of manufacture, so it may contain serotype 1, 2, 4 or 8 or a combination of any two of these. 
Vrsta (serotip) virusa v cepivu je izbrana glede na to, kateri serotipi krožijo in povzročajo obolenje v času proizvodnje cepiva, zato lahko vsebuje serotip 1, 2, 4 ali 8 oziroma katero koli kombinacijo dveh serotipov.
BTVPUR is a vaccine used in sheep and cattle to protect them against bluetongue disease, an infection caused by the bluetongue virus which is transmitted by midges. 
Zdravilo BTVPUR je cepivo, ki se uporablja pri ovcah in govedu za zaščito pred boleznijo modrikastega jezika, tj. okužbo, ki jo prenašajo trzače, povzroča pa jo virus modrikastega jezika.
The studies showed that the vaccine is safe for sheep and cattle and that it reduces the signs of the disease and prevents viraemia in animals from one month of age that are infected with bluetongue virus serotypes 1, 4 and 8. 
Študije so pokazale, da je cepivo varno za uporabo pri ovcah in govedu ter da zmanjšuje znake bolezni in preprečuje viremijo pri živalih, starejših od enega meseca, ki so okužene s serotipi 1, 4 in 8 virusa modrikastega jezika.
The studies also showed that the vaccine can be used in pregnant and lactating sheep and cattle. 
Pokazale so tudi, da se cepivo lahko uporabi pri brejih ovcah in govedu ter tistih v laktaciji.
The first injection is given from one month of age in animals that have never been exposed to the disease, and from two-and-a-half months if the animal's mother is already immune to the disease and has bluetongue virus antibodies. 
Živali, ki še nikoli niso bile izpostavljene bolezni, prejmejo prvo injekcijo od enega meseca starosti dalje, mladiči mater, ki so že imune proti bolezni in imajo protitelesa proti virusu modrikastega jezika, pa od starosti dveh mesecev in pol dalje.
Further laboratory studies were conducted in calves using a vaccine containing bluetongue serotype 2 and in sheep and calves using a vaccine containing bluetongue serotype 4. 
Nadaljnje laboratorijske študije so izvedli pri teletih, kjer so uporabili cepivo s serotipom 2 virusa modrikastega jezika, ter pri ovcah in teletih z uporabo cepiva, ki vsebuje serotip 4 virusa modrikastega jezika.
BTVPUR contains bluetongue virus of one or two types selected from serotypes 1, 2, 4 and 8. 
Zdravilo BTVPUR vsebuje eno ali dve vrsti izbranih serotipov 1, 2, 4 in 8 virusa modrikastega jezika.
How is BTVPUR used? 
Kako se zdravilo BTVPUR uporablja?
The studies also showed that the vaccine reduces the signs of the disease in sheep and prevents viraemia in sheep and cattle from one month of age that are infected with bluetongue virus serotype 2. 
Poleg tega so študije pokazale, da cepivo zmanjšuje znake bolezni pri ovcah ter preprečuje viremijo pri ovcah in govedu, starejših od enega meseca, ki so okuženi s serotipom 2 virusa modrikastega jezika.
The effectiveness of the vaccine was studied in laboratory studies using vaccines containing bluetongue serotype 1, bluetongue serotype 8, or both, in sheep and cattle of young age. 
Učinkovitost cepiva so proučevali v laboratorijskih študijah, v katerih so pri mladih ovcah in govedu uporabljali cepiva, ki vsebujejo serotip 1, serotip 8 ali oba serotipa virusa modrikastega jezika.
(Bluetongue virus inactivated vaccine containing either serotype 1, 2, 4 or 8 or a combination of any two) 
BTVPUR1 (inaktivirano cepivo proti virusu modrikastega jezika, ki vsebuje serotip 1, 2, 4 ali 8 oziroma katero koli kombinacijo dveh serotipov)
How does BTVPUR work? 
Kako zdravilo BTVPUR deluje?
Date of latest renewal: 28 November 2017 
Datum zadnjega podaljšanja: 28. november 2017
The signs of pandemic flu are similar to those of ordinary flu but may be more serious. 
Znaki pandemske gripe so podobni znakom običajne gripe, vendar pa so lahko resnejši.
Special population: 
Posebne populacije:
• Serious stabbing or throbbing pain along one or more nerves 
• resna zbadajoča ali kljuvajoča bolečina vzdolž enega ali več živcev;
In the first few weeks after vaccination with Prepandrix the results of these tests may not be correct. 
V prvih nekaj tednih po cepljenju s cepivom Prepandrix so lahko rezultati teh preiskav napačni.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 14 May 2008 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve odovritve: 16. maj 2008
It is best to see how Prepandrix affects you before you try these activities. 
Najbolje je, da ugotovite, kako cepivo Prepandrix vpliva na vas, preden opravljate te dejavnosti.
The use of Prepandrix may be considered during pregnancy if this is thought to be necessary taking into account official recommendations. 
Cepivo Prepandrix se lahko uporabi med nosečnostjo, če se oceni, da je potrebno in ob upoštevanju uradnih priporočil.
See sections 4.4, 4.8 and 5.1. 
Glejte poglavja 4.4, 4.8 in 5.1.
Prepandrix should be used in accordance with official guidance. 
Cepivo Prepandrix je treba uporabljati v skladu z uradnimi smernicami.
Read all of this leaflet carefully before you receive this vaccine because it contains important information for you. 
Preden dobite to cepivo, natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
The safety and efficacy of Prepandrix in children aged less than 3 years and in children and adolescents aged 10 to 17 years have not been established. 
Pediatrična populacija Varnost in učinkovitost cepiva Prepandrix pri otrocih, mlajših od treh let, in pri otrocih in mladostnikih v starosti od 10 do 17 let, nista ugotovljeni.
See sections 4.4, 4.8 and 6.1. 
Glejte poglavja 4.4, 4.8 in 6.1.
Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines or have recently received any other vaccine. 
Obvestite svojega zdravnika ali medicinsko sestro, če jemljete, ste pred kratkim jemali, boste morda začeli jemati katerokoli zdravilo, ali pa ste pred kratkim dobili kakršnokoli drugo cepivo..
MARKETING AUTHORISATION NUMBER(S) EU/1/08/453/002 
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/08/453/002
For any information about this vaccine, please contact the local representative of the Marketing Authorisation Holder: 
Za vse morebitne nadaljnje informacije o tem cepivu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom:
Pandemic flu is a type of influenza that happens at intervals that vary from less than 10 years to many decades. 
Pandemska gripa je vrsta gripe, ki se pojavi v presledkih, ki trajajo od manj kot 10 let do več desetletij, in se hitro širi po vsem svetu.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you receive this vaccine 
Če ste noseči ali dojite, menite, da ste noseči ali načrtujete zanositev, se posvetujte s svojim zdravnikom, preden dobite to cepivo.